Regeneron

2,123

$473.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$23.85 (+5.31%) As of 3:33 PM EDT today

+$23.85 (+5.31%) Today

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

CEO

Leonard S. Schleifer

Employees

8,100

Headquarters

Tarrytown, New York

Founded

1988

Market Cap

47.28B

Price-Earnings Ratio

24.35

Dividend Yield

—

Average Volume

2.16M

High Today

$476.10

Low Today

$461.00

Open Price

$463.09

Volume

1.06M

52 Week High

$518.00

52 Week Low

$271.37

Collections

REGN News

CNBC3h

Stocks making the biggest moves midday: Johnson & Johnson, Eldorado Resorts, Regeneron & more

Check out the companies making headlines midday Monday: Johnson & Johnson — Johnson & Johnson shares jumped more than 7% after the company announced it has a c

196

Benzinga4h

Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ -- Results from separate positive Phase 3 trial of Praluent® (alirocumab) in patients with HoFH also presented; FD

295

MarketWatch8h

First patient treated in Regeneron, Sanofi trial for COVID-19 treatment

Regeneron Pharmaceuticals Inc. REGN, -0.61% and Sanofi SA SNY, -1.19% said Monday that the first patient in a global clinical trial testing Kevzara as a therapy

1,126

Analyst Ratings

46%

of 24 ratings

Buy

46%

Hold

50%

Sell

REGN Earnings

$0.00

$2.50

$5.00

$7.50

Q2 2018

Q3 2018

Q4 2018

Q1 2019

Q2 2019

Q3 2019

Q4 2019

Q1 2020

Estimated

— per share

Actual

Expected May 5, Pre-Market

People Also Bought

Gilead Sciences

42,324

$75.80

+4.05%

Gilead Sciences

42,324

$75.80

+4.05%

Bristol-Myers Squibb

10,010

$54.59

+3.40%

AbbVie

30,953

$75.29

+3.60%

Biogen

1,787

$320.09

+7.87%

More REGN News

CNBCMar 27

Developing a vaccine takes 10 years. Sanofi seeks to do so within 18 months

The process to develop a vaccine typically takes a decade, but an untypical circumstance is calling for it to be done in a fraction of the time, the head of a F

904

BloombergMar 26

Regeneron Says FDA Moving Quickly on Potential Coronavirus Treatments

Mar.26 -- Dr. George Yancopoulos, Regeneron co-founder and chief scientific officer, talks about how the company is working with the FDA to find treatments for

1,174

Learn Blog Careers Help Log In Sign Up

Regeneron

$473.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

Why Robinhood?

About REGN

Collections

REGN News

Stocks making the biggest moves midday: Johnson & Johnson, Eldorado Resorts, Regeneron & more

Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

First patient treated in Regeneron, Sanofi trial for COVID-19 treatment

Analyst Ratings

46%

REGN Earnings

People Also Bought

$75.80

$75.80

$54.59

$75.29

$320.09

You May Also Like

More REGN News

Developing a vaccine takes 10 years. Sanofi seeks to do so within 18 months

Regeneron Says FDA Moving Quickly on Potential Coronavirus Treatments

Buy REGN